ABSTRACT
In this work, we proposed a variant of the SIR model, taking as based on models used to describe the epidemic outbreak in South Korea and Portugal, to study the COVID-19epidemic curve in Brazil. The model presented here describes with reasonable agreement the number of COVID-19 cases registered in Brazil between February 26 and May 18, 2020 based on the hypothesis that there a large number no notified cases (11 to 1) and variation in contagion rate according to social isolation measures and greater or lesser exposure to the virus (highest rate in beginning from epidemic). To this end, we introduced an exposure factor, called β1/β2, which allows us to describe the influence of factors such as social isolation on dispersal from disease. The results also corroborate a phenomenon observed in countries that registered a high growth in cases in short period of time, to example of Italy, Spain and USA: if isolation measures are imposed late, the total number of cases explodes when the epidemic is approaching from peak, which implies a higher exposure rate in the first days of case registration. From the data collected, we made the linear adjustment of the infected curve according to the time between the 41st and 74th days since the official notification of the first case and we obtained a high infection rate in the period, close to 4.0. The result indicates that the relaxation of social exclusion measures contributed to the high increase in cases in the period. This result reinforces the adoption of the model that differentiates unexposed susceptible from those that are most exposed to contagion. The model also predicts that the peak epidemic outbreak in Brazil, based on the number of cases, will occur around in late May and early June.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research only involves theoretical epidemiological data, no IRB oversight is required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are openly available in Painel Coronavirus at https://covid.saude.gov.br/
